Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab Vedotin + R-CHP vs R-CHOP in Previously Untreated DLBCL
NCT06717347Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Primary completion
- Jul 2029
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 35
01
Overview
A Phase 3 trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Merck & Co.. Started Jan 2025; status: recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06717347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717347.